STAT+: Kyverna’s cell therapy shows lasting autoimmune benefit
Kyverna Therapeutics is one step closer to launching the first cell therapy for an autoimmune disease, with new data in hand showing many patients remained off of other therapies a…
This item is an automated import from an external feed and has not yet been rewritten into a neutral C-IT-ALL summary. Read the full story at the original source below.
Read the full story at STAT News
Related Coverage